Skip to main content

Table 4 The treatment of patients who are progressing and those who are stable [39]

From: Clinical progression of patients with COVID-19 in Lagos State, Nigeria

  Total (N = 1337) Mild‑moderate (N = 1000) Severe‑critical (N = 337) P value
Treatment 1337 1000 337  
Antiviral therapy
 Antibiotic therapy 109 (8.15%) 61 (4.56%) 58 (4.33%)  < 0.002
 Use of corticosteroid 99 (7.40%) 32 (2.39%) 78 (5.83%)  < 0.002
 Use of gamma globulin 91 (6.80%) 28 (2.09%) 73 (5.54%)  < 0.002
 Regulate intestinal flora 189 (14.13%) 133 (9.94%) 66 (4.93%)  < 0.002
 Oxygen support 248 (18.54%) 170 (12.71%) 89 (6.65%)  
 Nasal cannula 191 (14.28%) 167 (12.49%) 33 (2.46%)  < 0.002
 Mask oxygen inhalation 9 (0.67%) 5 (0.37%) 4 (0.29%) 0.047
 High-flow nasal cannula 12 (0.89%) 0 10 (0.74%)  
 Non-invasive ventilation 26 (1.94%) 0 28 (2.09%)  
 Invasive mechanical ventilation 13 (0.97%) 0 16 (1.19%)  
 Invasive mechanical ventilation + ECOM 7 (0.52%) 0 7 (0.52%)  
 IL-6 (pg/mL) 10(0.74%) 4(0.4%) 6(1.7%)  < 0.001
 Acute respiratory distress syndrome 16 (1.19%) 0 16 (1.19%)